BSX
BOSTON SCIENTIFIC CORP
Healthcare • CIK: 0000885725
Loading...
Market Cap
$93.02B
P/E (TTM)
26.1x
Rev Growth (TTM)
+17.4%
Net Margin (TTM)
17.3%
FCF Yield (TTM)
3.7%
FCF Margin (TTM)
16.9%
Cash Flow Health
Free Cash Flow8/8 positive
TTM$3.5B
Q1 '26
$171M-83%
Q4 '25
$1.0B-13%
FCF Margin
TTM16.9%
Q1 '263.3%-83%
Sector: 0.0%Top 10%
OCF Margin21.1%
OCF/NI1.22x
CapEx Coverage5.0x
FCF Yield3.7%
FCF Growth (2Y)+43%
Cash Conversion Cycle
108 days
DSO: 0+DIO: 168−DPO: 60
Capital Allocation & Returns
Total Shareholder Yield
TTM0.0%
Div Yield0.0%
Insufficient data
Dividend & Payout Metrics
Dividend Yield (TTM)0.0%
Free Cash Flow (TTM)$3.5B
Capital Return / FCF0.0%
Est. Dividends Paid (TTM)$0
Shows how management rewards shareholders
Operational Efficiency & Returns
Return on Invested CapitalTTM
10.3%
Stable
+0.0% YoY+6.4%
P25MedianP75
75th pctl (med: -0.0%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
17.5%
8Q: 14.6%
Asset Turnover
0.48x
8Q: 0.47x
Leverage (1+D/E)
1.43x
D/E: 0.43x
DuPont: 12.1% ≈ 10.3% ROIC
Asset & CapEx Efficiency
Fixed Asset Turn
5.49x
8Q:5.59x
-37.9%
Invested Cap Turn
0.64x
8Q:0.64x
Flat
CapEx Intensity
2.7%
8Q:2.4%
CapEx/Depreciation
0.62x
Asset-based ROIC formula
QUARTERLY TRENDS
Last 8 quarters + TTM
| Metric | TTM | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | $20.6B | $5.2B↓1.6% | $5.3B↑4.4% | $5.1B↑0.1% | $5.1B↑8.5% | $4.7B↑2.2% | $4.6B↑8.4% | $4.2B↑2.2% | $4.1B |
Operating Income | $3.8B | $1.1B↑33.5% | $825.0M↓21.3% | $1.0B↑28.0% | $819.0M↓11.1% | $921.0M↑36.4% | $675.0M↓7.9% | $733.0M↑41.0% | $520.0M |
Net Income | $3.6B | $1.3B↑99.6% | $672.0M↓11.0% | $755.0M↓5.3% | $797.0M↑18.2% | $674.0M↑19.3% | $565.0M↑20.5% | $469.0M↑44.8% | $324.0M |
Operating Cash Flow | $4.3B | $348.0M↓74.5% | $1.4B↑1.6% | $1.3B↑4.4% | $1.3B↑137.7% | $541.0M↓62.8% | $1.5B↑45.3% | $1.0B↑23.2% | $813.0M |
Free Cash Flow | $3.5B | $171.0M↓83.1% | $1.0B↓12.8% | $1.2B↑2.9% | $1.1B↑218.9% | $354.0M↓70.0% | $1.2B↑43.3% | $823.0M↑25.1% | $658.0M |
Total Equity | N/A |
Valuation Analysis
Fair Value
Price-to-EarningsTTM
26.1x
Volatile
8Q: 214.8x-19708%
Valuation Lenses
Earnings
26.1x
vs – sector
Cash Flow
29.7x
EV/FCF vs –
Growth-Adj
0.3xPEG
Undervalued for growth
Quality-Adj
2.5P/E per %ROIC
ROIC: 10.3%
Shareholder Returns
Dividend
–
Buyback
–
Total Yield
–
Market Cap$93.02B
EV$103.05B
Multi-angle valuation analysis with sector context
Business Quality & Moat
Overall Quality Score
82/100
Exceptional
Composite score: Returns (40%) + Consistency (30%) + Earnings Quality (30%)
Returns on Capital
Return on Equity (ROE)Top 25%
15.2%
8Q:–
Return on Invested Capital (ROIC)Top 25%
10.3%
8Q:–
+6.4%
vs Sector:-0.0%
DuPont Analysis (ROIC = NOPAT Margin × Asset Turnover)
NOPAT Margin: 17.5%
Asset Turnover: 0.48x
Earnings Quality
Cash Conversion
1.22x
OCF / Net Income ✓
FCF Consistency
–
Positive quarters
Competitive Moat Indicators
Pricing Power
Gross Margin69.2%
Capital Efficiency
Invested Capital Turnover0.64x
Working Capital
Cash Conversion Cycle108 days
Growth Quality & Momentum
Quality Growth
Growth Quality Score
77/100
Growth 40%
Margins 30%
FCF 20%
Consistency 10%
Growth Rates
Revenue Growth YoY
17.4%
OpInc Growth YoY
19.5%
EPS Growth YoY
74.7%
FCF 3Y CAGR
42.7%
Growth Quality Analysis
✓Efficient Growth: Free cash flow growing faster than revenue
✓Sustainability Index: 7.5/10 - Highly sustainable growth
Margin Quality & Sustainability
High Quality
Profitability Cascade
Gross
69.2%
Operating
18.4%
Top 25% in sector
Net
17.3%
Margins Unknown
Earnings Quality Signals
SBC / Revenue
—
FCF vs Net Gap
-0.4 pts
FCF: 16.9% | Net: 17.3%
Quality = stability + cash conversion + low dilution
Balance Sheet & Solvency
Adequate
Net Debt / EBITDA
–Net Debt: $9.39B
Interest Coverage
–
Leverage Metrics
Debt-to-Equity
0.43x
Balance sheet risk & solvency analysis